The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 21, 2015
Filed:
Sep. 15, 2014
Applicant:
Proteotech Inc., Kirkland, WA (US);
Inventors:
Esposito A Luke, Seattle, WA (US);
Marisa C Yadon, Brea, ZA;
Joel Cummings, Seattle, WA (US);
F Michael Hudson, Oakland, CA (US);
Thomas Lake, Snohomish, WA (US);
Qubai Hu, Kirkland, WA (US);
Judy Cam, Bellevue, WA (US);
Alan D. Snow, Lynnwood, WA (US);
Assignee:
PROTEOTECH INC, Kirkland, WA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 39/15 (2006.01); C07D 333/16 (2006.01); A61K 31/05 (2006.01); A61K 31/381 (2006.01); C07D 263/56 (2006.01); C07C 255/53 (2006.01); C07D 231/06 (2006.01); C07C 205/20 (2006.01); C07C 205/22 (2006.01); C07D 333/28 (2006.01); C07D 409/14 (2006.01); C07D 249/06 (2006.01); C07D 263/32 (2006.01); C07C 235/56 (2006.01); C07D 263/57 (2006.01); C07D 271/10 (2006.01); C07D 271/107 (2006.01); C07D 277/24 (2006.01); C07D 277/32 (2006.01); C07D 285/08 (2006.01); C07D 285/12 (2006.01); A61J 1/00 (2006.01);
U.S. Cl.
CPC ...
C07D 333/16 (2013.01); A61J 1/00 (2013.01); C07C 39/15 (2013.01); C07C 205/20 (2013.01); C07C 205/22 (2013.01); C07C 235/56 (2013.01); C07C 255/53 (2013.01); C07D 231/06 (2013.01); C07D 249/06 (2013.01); C07D 263/32 (2013.01); C07D 263/56 (2013.01); C07D 263/57 (2013.01); C07D 271/10 (2013.01); C07D 271/107 (2013.01); C07D 277/24 (2013.01); C07D 277/32 (2013.01); C07D 285/08 (2013.01); C07D 285/12 (2013.01); C07D 333/28 (2013.01); C07D 409/14 (2013.01);
Abstract
Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.